Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

May 16, 2023 by Alan Khadavi

Xolair vs. Nucala vs. Dupixent in Asthma, which is the best?

Xolair vs. Nucala vs. Dupixent

Multiple biologics are approved for the the treatment of severe asthma. However, there are no head to head studies comparing them. Many patients can potentially be approved for multiple of them and it can be difficult to choose which would work best. So the optimal choice may be uncertain.

All currently approved asthma biologic therapies have been shown to improved asthma-related outcomes in patients who are not controlled with conventional therapies.

  • Xolair (omalizumab) is an anti-IgE that is approved for allergic asthma who have sensitivity to perennial allergens and their IgE level is between 3-700 kU/L.
  • Dupixent (dupilumab) is an anti IL-4 receptor alpha for patients with allergic and eosinophilic asthma.
  • Nucala (mepolizumab) is an anti-IL-5 that is effective in eosinophilic asthma in patients whose eosinophils are at least 150 cells/microliter.

Without head to head studies it is hard to make an effective clinical decision. A recent study reported in the Journal of Allergy and Clinical Immunology performed a retrospective clinical study of all 3 of them and compared asthma-related exacerbations and improving lung function in individuals with asthma.

The conclusions of the study found:

  • Dupixent was associated with greater reductions in exacerbations that Nucala and Xolair.
  • Dupixent was associated with greater than 100ml improvement in FEV1 value compared with Nucala, although this did not meet statistical significance threshold.

They concluded that Dupixent may be a better choice for eligible patients in patients with eosinophils at least at 150 cells and IgE between 30 to 700 kU/L.

In past articles we have discussed other head to head studies.

Tezspire vs. Nucala vs. Fasenra vs. Dupixent for Eosinophilic Asthma, a comparison

Nucala vs. Fasenra vs. Cinqair; A Comparison Study

Nucala (mepolizumab) vs. Cinqair (reslizumab)

There are many factors involved when choosing the right biological medication for asthma, co-morbid conditions also play a role, although in this study those patients were not included.

If you suffer from asthma that isn’t well controlled with maintenance asthma inhalers, speak to your doctor or asthma specialist about other treatment options.

Filed Under: Asthma, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

September 22, 2023

How to treat Eosinophilic Esophagitis (EoE)

eosinophilic esophagitis treatment

September 14, 2023

Barley Allergy: Diagnosis and Management

barley allergy

September 11, 2023

Can the Covid Vaccine cause Hives?

covid vaccine and hives

August 30, 2023

Hops Allergy: Etiology, Presentation & Management

hops allergy

August 29, 2023

Dupixent for COPD, a new indication

dupixent for copd

August 10, 2023

Is Singulair Safe to Use? A study of Montelukast

Is Singulair safe?

July 24, 2023

Why am I so Itchy? Management of Chronic Itch

chronic itch

July 19, 2023

Potato Allergy: Can I be allergic to Potatoes?

potato allergy

July 18, 2023

Blueberry Allergy, can I be allergic to it?

blueberry allergy

June 30, 2023

Coffee Allergy: Can you be allergic to it?

coffee allergy

Read More Posts...

Follow Us…

© 2023 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page